Alzamend Neuro Inc - ESG Rating & Company Profile powered by AI
The assessment of Alzamend Neuro Inc is prepared by All Street Sevva using cutting edge AI. This ESG score covers 17 United Nations SDGs including: 'Affordable & Clean Energy', 'Decent Work & Economic Growth' and 'Partnerships for the Goals'. Full ESG analysis of Alzamend Neuro Inc are reached by signing in.
Alzamend Neuro Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 3.9; made up of an environmental score of 2.0, social score of 4.8 and governance score of 4.8.
3.9
Low ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| 1004 | Xeris Pharmaceuticals Inc | 4.0 | High |
| 1004 | Xenon Pharmaceuticals Inc | 4.0 | High |
| ... | ... | ... | |
| 1089 | Alzamend Neuro Inc | 3.9 | Medium |
| 1089 | Aclaris Therapeutics Inc | 3.9 | Medium |
| 1089 | Allogene Therapeutics Inc | 3.9 | Medium |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Alzamend Neuro Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Alzamend Neuro Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Alzamend Neuro Inc report the average age of the workforce?
Sign up for free to unlockDoes Alzamend Neuro Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Alzamend Neuro Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Alzamend Neuro Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Alzamend Neuro Inc offer flexible work?
Sign up for free to unlockDoes Alzamend Neuro Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Alzamend Neuro Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Alzamend Neuro Inc conduct supply chain audits?
Sign up for free to unlockDoes Alzamend Neuro Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Alzamend Neuro Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Alzamend Neuro Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Alzamend Neuro Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Alzamend Neuro Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Alzamend Neuro Inc disclose water use targets?
Sign up for free to unlockDoes Alzamend Neuro Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Alzamend Neuro Inc have a product recall in the last two years?
Sign up for free to unlockDoes Alzamend Neuro Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Alzamend Neuro Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Alzamend Neuro Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Alzamend Neuro Inc disclose parental leave metrics?
Sign up for free to unlockDoes Alzamend Neuro Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Alzamend Neuro Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Alzamend Neuro Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Alzamend Neuro Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Alzamend Neuro Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Alzamend Neuro Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Alzamend Neuro Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Alzamend Neuro Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Alzamend Neuro Inc disclose its waste policy?
Sign up for free to unlockDoes Alzamend Neuro Inc report according to TCFD requirements?
Sign up for free to unlockDoes Alzamend Neuro Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Alzamend Neuro Inc disclose energy use targets?
Sign up for free to unlockDoes Alzamend Neuro Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Alzamend Neuro Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Alzamend Neuro Inc
These potential risks are based on the size, segment and geographies of the company.
Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001 that is in Phase II clinical trial, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and AL002 that completed preclinical stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.